|
Multiple Myeloma
|
0.340 |
Biomarker
|
disease |
BEFREE |
Incorporation of CTLA4Ig in conditioning aided long-term remission in myeloma probably by blocking the CD28-CD86 pro-survival pathway when combined with CTLA4Ig-primed DLI.
|
31449833 |
2019 |
|
Multiple Myeloma
|
0.340 |
Biomarker
|
disease |
BEFREE |
CD86 regulates myeloma cell survival.
|
29296880 |
2017 |
|
Multiple Myeloma
|
0.340 |
Biomarker
|
disease |
BEFREE |
Consistent with these observations, in vivo blockade of CD28-CD80/CD86 in the Vk*MYC murine myeloma model sensitizes MM cells to chemotherapy and significantly reduces tumor burden.
|
24782505 |
2014 |
|
Multiple Myeloma
|
0.340 |
Biomarker
|
disease |
CTD_human |
Circulating levels and clinical significance of soluble CD86 in myeloma patients.
|
16611307 |
2006 |
|
Multiple Myeloma
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
The yield as well as the pattern and intensity of Ag (HLA-DR, CD40, CD54, CD80, and CD86) expression were equivalent on DCs from BM or PB of MM patients versus normal donors.
|
10029575 |
1999 |
|
Gastro-enteropancreatic neuroendocrine tumor
|
0.300 |
Biomarker
|
disease |
CTD_human |
A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors.
|
29915428 |
2018 |
|
Contact Dermatitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Genes specifically modulated in sensitized skins allow the detection of sensitizers in a reconstructed human skin model. Development of the SENS-IS assay.
|
25724174 |
2015 |
|
Contact hypersensitivity
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Genes specifically modulated in sensitized skins allow the detection of sensitizers in a reconstructed human skin model. Development of the SENS-IS assay.
|
25724174 |
2015 |
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Liver diseases
|
0.300 |
Biomarker
|
group |
CTD_human |
Blood gene expression markers to detect and distinguish target organ toxicity.
|
19784758 |
2010 |
|
Liver Dysfunction
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Blood gene expression markers to detect and distinguish target organ toxicity.
|
19784758 |
2010 |
|
Asthma
|
0.230 |
Biomarker
|
disease |
RGD |
Boosting airway T-regulatory cells by gastrointestinal stimulation as a strategy for asthma control.
|
20668438 |
2011 |
|
Asthma
|
0.230 |
GeneticVariation
|
disease |
BEFREE |
A number of SNPs in the IL10, CYP24A1, CYP2R1, IL1RL1 and CD86 genes were modestly associated with asthma and atopy (p < 0.05).
|
19852851 |
2009 |
|
Asthma
|
0.230 |
GeneticVariation
|
disease |
BEFREE |
The CD86 gene, and specifically the Ile179Val polymorphism, may be a novel aetiological factor in the development of asthma and related allergic disorders.
|
17513529 |
2007 |
|
Asthma
|
0.230 |
GeneticVariation
|
disease |
LHGDN |
The CD86 gene, and specifically the Ile179Val polymorphism, may be a novel aetiological factor in the development of asthma and related allergic disorders.
|
17513529 |
2007 |
|
Asthma
|
0.230 |
Biomarker
|
disease |
LHGDN |
(4) In asthma group there was a significantly positive correlation of CD86 MFI on CD(14)(+) cell with CD19 and CD86 double positive cell percentage (r = 0.644), there was a significantly positive correlation of CD(19)(+)CD(86)(+)cells percentage with plasma total IgE (r = 0.537); there was a significantly positive correlation of CD(19)(+)cells percentage with the levels of IL-4 and IL-13 (r = 0.607, 0.540 respectively); a significantly positive correlation of CD(19)(+)CD(86)(+) percentage cells with the levels of IL-4 and IL-13 was found (r = 0.617, 0.678, respectively).
|
15059478 |
2004 |
|
Neoplasm Metastasis
|
0.220 |
Biomarker
|
phenotype |
BEFREE |
<b>Conclusion:</b> Genes in C3 play an important role in OS metastasis, whereas CD86 might be a potential molecular biomarker for OS metastasis.
|
31440272 |
2019 |
|
Neoplasm Metastasis
|
0.220 |
Biomarker
|
phenotype |
BEFREE |
A clear population of Mo-MDSCs with the typical cell surface phenotype (CD14(+)HLA-DR(low/-)CD86(low/-)CD80(low/-)CD163(low/-)) increased significantly first during disease progression and correlated to metastasis to lymph nodes and visceral organs.
|
25992611 |
2015 |
|
Neoplasm Metastasis
|
0.220 |
Biomarker
|
phenotype |
RGD |
In this setup, which excludes direct oncolytic effects on metastases, the JabCG2 vector displayed enhanced immunogenicity, inducing markers of cellular immunity (IFN gamma) and dendritic cell activation (CD80, CD86) in mediastinal (tumour-draining) lymph nodes.
|
18360875 |
2008 |
|
Adult T-Cell Lymphoma/Leukemia
|
0.210 |
AlteredExpression
|
disease |
BEFREE |
Similarly, CD86 expression on both mDCs and pDCs was significantly higher in HAM/TSP (but not ATL) patients compared to ACs.
|
23750452 |
2013 |
|
Adult T-Cell Lymphoma/Leukemia
|
0.210 |
Biomarker
|
disease |
RGD |
Development of human T-cell leukemia virus type 1-transformed tumors in rats following suppression of T-cell immunity by CD80 and CD86 blockade.
|
10590132 |
2000 |
|
Corneal Diseases
|
0.200 |
Biomarker
|
group |
RGD |
Cauterization of central cornea induces recruitment of major histocompatibility complex class II+ Langerhans cells from limbal basal epithelium.
|
19907296 |
2010 |
|
Dental Pulp Exposure
|
0.200 |
Biomarker
|
disease |
RGD |
Increased gene expression of Toll-like receptors and antigen-presenting cell-related molecules in the onset of experimentally induced furcation lesions of endodontic origin in rat molars.
|
20113783 |
2010 |
|
Dental Pulp Exposure
|
0.200 |
Biomarker
|
disease |
RGD |
Artificial dental pulp exposure injury up-regulates antigen-presenting cell-related molecules in rat central nervous system.
|
20171363 |
2010 |
|
Experimental Autoimmune Encephalomyelitis
|
0.200 |
ModifyingMutation
|
disease |
RGD |
Activated microglial cells acquire an immature dendritic cell phenotype and may terminate the immune response in an acute model of EAE.
|
20451260 |
2010 |